Zephyr Health has closed a $17.5 million Series C funding bringing the total money raised to date to $33.5 million. Google Ventures led the round with participation from current investors Kleiner Perkins Caufield & Byers and Icon Ventures.

On average it costs pharmaceutical companies between $1.5 and 2.4 billion to bring a new therapy to market, with only 33% of those products meeting their initial sales goals. Zephyr’s Illuminate solution improves business results across the product lifecycle; it does that by integrating thousands of public and private data sources to provide deep, predictive insights that enable customers to accelerate time to market for drugs, diagnostics and devices.

“With the support of Google Ventures, along with KPCB and Icon, we look forward to a collaborative partnership that will allow us to tap into their vast resources of knowledge and experience, helping us to further expand our business with new products and in new areas,” said William King, Founder and CEO, Zephyr Health.

The company’s clients include such firms as Genentech, Gilead, Medtronic, Onyx and Amgen.